10-Q: Lightwave Logic Reports Q3 2026 Results, Net Loss Widens

Sentiment:

Quarterly Report


Lightwave Logic, Inc. reported its third-quarter 2026 financial results, showing an increase in net sales but a significant widening of its net loss, driven by higher operating expenses.

Capital raiseThe company has historically satisfied its capital requirements through the issuance and sale of common stock.Proceeds from the sale of common stock to Titan Partners Group LLC (underwriting) and Roth Capital Partners, LLC (at-the-market sales agreement) provided significant cash inflows.The company received $27,883,977 in net proceeds from the Roth Sales Agreement during the nine months ended September 30, 2026.The company received $4,930,928 in net proceeds from the exercise of an over-allotment option from the Titan Offering in January 2026.Warrants were exercised, providing $1,362,932 in net proceeds.Options were exercised, providing $6,948,719 in proceeds.The company has $3,385 in shares remaining available for sale under the amended Roth Sales Agreement as of September 30, 2026.
Worse than expectedNet loss increased by 42% for the three months ended September 30, 2026, compared to the same period in 2025.Net loss increased by 36% for the nine months ended September 30, 2026, compared to the same period in 2025.Operating expenses, including R&D and G&A, saw significant percentage increases in both the three-month and nine-month periods, indicating rising costs without a commensurate increase in revenue.While revenue increased, it remains at very low levels ($37,500 for the quarter), highlighting the company's pre-commercialization stage and continued reliance on external funding.

Summary

  • Lightwave Logic, Inc. reported net sales of $37,500 for the three months ended September 30, 2026, an increase from $29,166 in the same period of 2025.
  • The net loss for the third quarter of 2026 was $7,221,953, a substantial increase from $5,100,559 in the third quarter of 2025.
  • For the nine months ended September 30, 2026, net sales were $99,418, up from $77,688 in the prior year period.
  • The net loss for the nine months ended September 30, 2026, was $20,136,290, compared to $14,764,216 for the same period in 2025.
  • Operating expenses, including research and development and general and administrative costs, increased significantly in both the three-month and nine-month periods.
  • The company's cash and cash equivalents stood at $17,566,678 as of September 30, 2026, with marketable securities totaling $70,277,228.
  • The company expects to have sufficient funds to finance operations at least through March 2028, based on current cash, financing proceeds, and expected commercial operations.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the significant increase in net loss and operating expenses, despite some revenue growth and improved cash position from financing activities. The company continues to operate at a substantial loss with no immediate prospect of significant commercial production revenue.

Positives

  • Net sales increased by 28.6% to $37,500 for the three months ended September 30, 2026, compared to $29,166 in the prior year period.
  • Net sales for the nine months ended September 30, 2026, increased by 27.7% to $99,418, compared to $77,688 in the prior year period.
  • The company's cash and cash equivalents and marketable securities totaled $87,843,906 as of September 30, 2026, providing a strong liquidity position.
  • The company expects its current funding to last at least through March 2028.
  • Proceeds from financing activities, including stock sales and warrant exercises, provided significant cash inflows during the nine months ended September 30, 2026, totaling $36,931,864.

Negatives

  • Net loss for the three months ended September 30, 2026, increased by 42% to $7,221,953 from $5,100,559 in the prior year period.
  • Net loss for the nine months ended September 30, 2026, increased by 36% to $20,136,290 from $14,764,216 in the prior year period.
  • Research and development expenses increased by 49% to $4,342,078 for the three months ended September 30, 2026.
  • General and administrative expenses increased by 61% to $3,677,238 for the three months ended September 30, 2026.
  • Total operating expenses for the nine months ended September 30, 2026, increased by 47% to $22,074,368.
  • The company has not yet achieved significant revenue from volume commercial production, with expectations for such revenue not before 2028.
  • Cost of sales increased to $705 for the three months ended September 30, 2026, from $0 in the prior year period, indicating early-stage production costs.

Risks

  • Inability to generate significant revenue or to manage growth.
  • Lack of available funding.
  • Lack of a market for or market acceptance of our products.
  • Competition from third parties.
  • General economic and business conditions.
  • Intellectual property rights of third parties.
  • Changes in the price of our stock and dilution.
  • Regulatory constraints and potential legal liability.

Future Outlook

The company anticipates that revenues, if any, recognized during 2026 would primarily relate to material supply, NRE arrangements, or prototype and development activities. Significant revenue from high-volume commercial production is not expected until 2028 at the earliest. Future expenditures will depend on R&D progress, commercialization pace, patent costs, market acceptance, and competitive developments.

Management Comments

  • We expect to continue to incur substantial research and development expenses developing and commercializing our electro-optic materials platform.
  • These expenses will increase because of accelerated development efforts to support commercialization of our electro-optic polymer materials technology and create next-generation photonic EO device designs; working with semiconductor foundries; hiring additional technical and support personnel; engaging senior technical advisors; pursuing other potential business opportunities and collaborations; customer testing and evaluation; and incurring related operating expenses.
  • We do not currently expect significant revenue from volume commercial production of customer products until 2028 at the earliest.
  • There can be no assurance that development-stage programs will transition to volume production, that anticipated timelines will be achieved, or that commercial revenues will occur as expected.

Industry Context

StockSavvy.ai notes that Lightwave Logic operates in the highly competitive and rapidly evolving silicon photonics and data transmission market. The company's focus on electro-optic polymers aims to offer advantages in speed, power consumption, and device footprint compared to traditional silicon-based or III-V technologies. However, the long development cycles and customer qualification processes typical in this industry are evident in the company's projected timeline for significant commercial revenue.

Comparison to Industry Standards

  • The company's projected timeline for significant commercial production revenue (not before 2028) aligns with the typical long development and qualification cycles in the advanced materials and semiconductor industries, where 'design wins' can take several years.
  • The reliance on material sales, IP licensing, and royalty-based arrangements is a common strategy for technology platform companies in the semiconductor and advanced materials sectors, aiming to leverage existing manufacturing infrastructure rather than investing heavily in their own fabrication facilities.
  • The company's stated goal of enabling high-speed optical modulation at low drive voltage and low power is a key performance indicator in the data center and telecommunications industries, where power efficiency and data throughput are critical competitive factors.

Management Changes

RolePrevious PersonNew PersonEffective DateReason
Class I directorEdward Kennedy2026-09-23Appointment by the Board of Directors.

Legal Proceedings

  • The company is not a party to any litigation of a material nature, nor is it aware of any threatened litigation of a material nature.

Related Party Transactions

  • No material transactions with related parties during the three- and nine-month periods ended September 30, 2026.
  • In the three and nine months ended September 30, 2025, transactions included legal fees, consulting fees, director compensation, accounting services, and expense reimbursements with consultants, directors, and affiliated entities.
  • As of December 31, 2025, accrued liabilities included $56,250 related to director compensation.

Stakeholder Impact

  • Shareholders may experience dilution due to ongoing stock sales and potential future capital raises.
  • Employees may see increased R&D and operational activities, with potential for future growth if commercialization is successful.
  • Customers are engaged in development programs, indicating potential for future adoption of the company's technology.
  • Suppliers of laboratory materials and fabrication services will likely see increased demand as R&D and production readiness activities continue.

Next Steps

  • Continue to advance research and development efforts.
  • Accelerate commercialization timeline.
  • Expand U.S. production capacity to support customer partnerships and design-ins.
  • Pursue strategic mergers and acquisitions or invest in complementary technologies or businesses.
  • Partner with commercial foundries to implement electro-optic polymers into accepted PDKs.
  • Develop and maintain collaborative relationships with strategic partners.
  • Develop and improve manufacturing processes and quality controls.
  • Continue to incur general and administrative activities related to operations as a public company.

Key Dates

DateDescription
2022-11-01Start of a period related to equipment not yet placed in service.
2022-11-22End of a period related to equipment not yet placed in service.
2022-12-08Sales Agreement entered into with an investment banking company.
2023-01-01Start of a period related to a joint development agreement.
2023-01-01Start of a period related to license agreements.
2023-01-01Start of a period related to sales agreements.
2023-01-01Start of a period related to software.
2023-01-01Start of a period related to USAgency Securities.

Recommendation

hold

The company shows technological promise in a growing market, evidenced by increasing sales and significant investment in R&D. However, the substantial and widening net loss, coupled with the long timeline to expected commercial production (2028 at the earliest), indicates significant risk and a need for continued funding. While the liquidity position is strong, the path to profitability remains uncertain, making a 'hold' recommendation appropriate for investors seeking growth but wary of pre-revenue stage risks.

Keywords

electro-optic polymers, photonic devices, silicon photonics, data transmission, optical modulation, lightwave logic, material sales, licensing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.